NasdaqGM - Delayed Quote • USD
MannKind Corporation (MNKD)
At close: May 17 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 4 | 4 | 4 |
| Avg. Estimate | 0.01 | 0.03 | 0.11 | 0.26 |
| Low Estimate | 0 | 0.03 | 0.09 | 0.2 |
| High Estimate | 0.02 | 0.05 | 0.17 | 0.38 |
| Year Ago EPS | -0.02 | 0.01 | -0.04 | 0.11 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 65.59M | 67.8M | 272.29M | 338.55M |
| Low Estimate | 62.3M | 64.2M | 262.7M | 321.1M |
| High Estimate | 73.78M | 75.5M | 295.46M | 360M |
| Year Ago Sales | 48.61M | -- | 198.96M | 272.29M |
| Sales Growth (year/est) | 34.90% | -- | 36.90% | 24.30% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.04 | -0.02 | 0 | 0.03 |
| EPS Actual | -0.02 | 0.01 | 0 | 0.04 |
| Difference | 0.02 | 0.03 | 0 | 0.01 |
| Surprise % | 50.00% | 150.00% | -- | 33.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.01 | 0.03 | 0.11 | 0.26 |
| 7 Days Ago | 0.03 | 0.04 | 0.14 | 0.23 |
| 30 Days Ago | 0.03 | 0.03 | 0.13 | 0.25 |
| 60 Days Ago | 0.03 | 0.03 | 0.1 | 0.25 |
| 90 Days Ago | 0.02 | 0.02 | 0.09 | 0.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 1 | 2 | 1 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 2 | 2 | -- |
Growth Estimates
| CURRENCY IN USD | MNKD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 150.00% | -- | -- | 8.00% |
| Next Qtr. | 200.00% | -- | -- | 12.40% |
| Current Year | 375.00% | -- | -- | 5.60% |
| Next Year | 136.40% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 35.60% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/9/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/15/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 |
| Initiated | Wedbush: Outperform | 10/10/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
Related Tickers
UTHR United Therapeutics Corporation
274.26
+0.75%
LQDA Liquidia Corporation
12.71
-0.24%
GERN Geron Corporation
3.8100
-2.31%
DTIL Precision BioSciences, Inc.
12.40
+3.51%
NRXP NRx Pharmaceuticals, Inc.
3.5400
+0.57%
ALT Altimmune, Inc.
8.01
-10.00%
BCRX BioCryst Pharmaceuticals, Inc.
6.29
-2.86%
AUPH Aurinia Pharmaceuticals Inc.
5.76
-0.17%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.6700
-2.34%
VSTM Verastem, Inc.
11.50
-5.19%